CHANTEST, INC.

Basic Information

14656 NEO PKY
CLEVELAND, OH, -

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car

    Amount: $1,184,308.00

    DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre- clinical cardiac safety testing. We have characterized a ...

    SBIR Phase II 2012 Department of Health and Human Services
  2. Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car

    Amount: $149,275.00

    DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre-clinical cardiac safety screening. We have recently charac ...

    SBIR Phase I 2010 Department of Health and Human Services
  3. Development of a Complete Proarrhythmic Safety Profile for Drugs

    Amount: $149,322.00

    DESCRIPTION (provided by applicant): ChanTest's goal is to commercialize a comprehensive non-clinical proarrhythmic profile that will screen compounds through a battery of models that span from the mo ...

    SBIR Phase I 2006 Department of Health and Human Services
  4. New drugs for treatment of atrial fibrillation

    Amount: $0.00

    DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cause of arrhythmias in the elderly; it has an incidence of more than 5 percent in people > 69 years of age. At present ...

    SBIR Phase I 2003 Department of Health and Human Services
  5. New drugs for treatment of atrial fibrillation

    Amount: $580,448.00

    DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cause of arrhythmias in the elderly; it has an incidence of more than 5 percent in people > 69 years of age. At present ...

    SBIR Phase II 2003 Department of Health and Human Services
  6. New drugs for treatment of atrial fibrillation

    Amount: $99,924.00

    Atrial fibrillation (AF) is the commonest cardiac arrhythmia and in its chronic form affects more than two million patients in the USA. AF is associated with cardiac and non-cardiac diseases. About 10 ...

    SBIR Phase I 2001 Department of Health and Human Services
  7. NOVEL SIMPLE SCREEN FOR POTASSIUM CHANNELS

    Amount: $89,263.00

    N/A

    SBIR Phase I 1998 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government